A Long-term Study of AK102 in Patients With Hypercholesterolemia

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 796 participants.

Also called NCT04173403

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 796 participants (enrolled count) (from the registry)
Sponsor
  • Akeso Registry lists this organization as the lead sponsor
Registry
  • NCT NCT04173403
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
China (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT04173403. Allocation not applicable; no masking; primary purpose treatment. Start 2019-11-04 (actual); primary completion 2023-02-17 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Long-term Study of AK102 in Patients With Hypercholesterolemia
Condition
Hypercholesterolemia
Intervention (Drug)
450mg AK102
Intervention (Drug)
300mg AK102
Intervention (Drug)
150mg AK102
Intervention (Drug)
Statins and/or Ezetimibe
Lead sponsor
Akeso (class: industry)
Collaborator
AD Pharma (Guangdong) (class: not stated)

Record details

Record id
cardio:ct-nct04173403
Content hash
d129ee7ebb3301cc479703760913f9a858824e7897e39c2ef9e0c2a1c982da16